to provide vaccination in high-risk countries such as Afghanistan, Chad, Ethiopia, the Democratic
Republic of the Congo, Nigeria and Pakistan. Similarly, in 2017, the Government of India launches
Pan-India Measles-Rubella vaccination campaign, under which children ages from 9 months to 15
years are vaccinated to reduce the incidence of these disease in children. Such initiatives by various
organizations and governments is expected to aid in growth of the market. Furthermore,
development of combinational vaccines could aid in reducing cost and adverse effects by reducing
the number of vaccination programme.
The global measles, mumps, and rubella vaccines market is segment on the basis of geography into
North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. According to the Pan
American Health Organization (PAHO), 2017, measles and rubella have been eliminated from the
Americas region, however, the challenge lies in preventing the outbreak. However, according to a
report by CDC’s National Center for Immunization and Respiratory Diseases (NCIRD), in 2014, the
U.S. recorded 667 number of measles cases from 27 states, which was the highest number of cases
since measles elimination was documented in the U.S. in 2000. This states that the vaccine
programs were unsuccessful in preventing the outbreak of the disease.
Key manufacturers in the measles, mumps, and rubella vaccine market are focusing on launching
new vaccines, in order to enhance their share in the market. According to Access to Medicine
Foundation index, 2017, vaccine market is dominated by four major players, collectively referred as
'big four': GSK, Merck & Co., Inc., Pfizer, and Sanofi. Big four contribute to 80% of the global
vaccine revenue. Players vary significantly by portfolio and pipeline size. Three of the four
companies have larger pipelines than Merck & Co., Inc. or Pfizer. In March 2107, GSK’s measles,
mumps, and rubella vaccine for indication of measles, mumps, and rubella prophylaxis was in phase
III trial, which is expected to commercialize in the forecast period of 2017 to 2025. Priorix and
Priorix Tetra Measles, mumps and rubella vaccine of GSK are expected to lose their patents in 2019
in the U.S. Some small players such as Daiichi Sankyo and Takeda are focusing on launching
vaccines for MMR in regional markets. For instance, Daiichi Sankyo’s VN-0102/JVC-001 is
measles, mumps, and rubella vaccine in phase I clinical trials as of May 2016.
Side effects related to vaccinations could be a major factor restraining growth of the measles,
mumps, and rubella vaccine market. For instance, in 1998, Japan stopped using trivalent
combinational measles, mumps and rubella vaccine due to outbreak of non-viral meningitis and
other damaging side effects which will restrict the MMR vaccine market. Moreover, high cost of
single dosage of vaccine is another restraining actor for the market growth. Factors such as limited
number of vaccines, stringent manufacturing and approval criteria as well as gap between demand
and supply during disease outbreak, and special storage and handling leading to high cost of
measles, mumps and rubella vaccines are major factors negatively affecting growth of the market.
Measles, Mumps, and Rubella Vaccine Market - Competitors
The major manufacturers with WHO prequalified measles, mumps, and rubella vaccines are
GlaxoSmithKline (Belgium), Merck & Co. Inc. (USA) and Serum Institute of India Ltd, among
others.
Measles, Mumps, and Rubella Vaccine Market Taxonomy:
By Product Type:
•Monovalent
•Combinational
•Divalent